Royalty Pharma (RPRX) Loans and Notes Receivables: 2019-2025
Historic Loans and Notes Receivables for Royalty Pharma (RPRX) over the last 6 years, with Sep 2025 value amounting to $860.1 million.
- Royalty Pharma's Loans and Notes Receivables rose 12.31% to $860.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $860.1 million, marking a year-over-year increase of 12.31%. This contributed to the annual value of $783.8 million for FY2024, which is 6.14% up from last year.
- Per Royalty Pharma's latest filing, its Loans and Notes Receivables stood at $860.1 million for Q3 2025, which was up 2.03% from $842.9 million recorded in Q2 2025.
- Over the past 5 years, Royalty Pharma's Loans and Notes Receivables peaked at $860.1 million during Q3 2025, and registered a low of $522.4 million during Q1 2021.
- In the last 3 years, Royalty Pharma's Loans and Notes Receivables had a median value of $742.2 million in 2023 and averaged $745.5 million.
- Data for Royalty Pharma's Loans and Notes Receivables shows a peak YoY rose of 16.58% (in 2022) over the last 5 years.
- Over the past 5 years, Royalty Pharma's Loans and Notes Receivables (Quarterly) stood at $614.4 million in 2021, then climbed by 12.53% to $691.3 million in 2022, then grew by 6.82% to $738.4 million in 2023, then climbed by 6.14% to $783.8 million in 2024, then increased by 12.31% to $860.1 million in 2025.
- Its Loans and Notes Receivables was $860.1 million in Q3 2025, compared to $842.9 million in Q2 2025 and $716.6 million in Q1 2025.